Control Empresarial De Capital Purchases 268,105 Shares of ProKidney Corp. (NASDAQ:PROK) Stock

ProKidney Corp. (NASDAQ:PROK - Get Free Report) insider Control Empresarial De Capital bought 268,105 shares of the firm's stock in a transaction that occurred on Monday, April 14th. The shares were purchased at an average price of $0.73 per share, for a total transaction of $195,716.65. Following the transaction, the insider now owns 72,862,330 shares of the company's stock, valued at $53,189,500.90. The trade was a 0.37 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Control Empresarial De Capital also recently made the following trade(s):

• On Wednesday, April 16th, Control Empresarial De Capital acquired 100,000 shares of ProKidney stock. The shares were purchased at an average price of $0.75 per share, with a total value of $75,000.00.
• On Thursday, April 10th, Control Empresarial De Capital bought 1,032,218 shares of ProKidney stock. The shares were purchased at an average price of $0.61 per share, with a total value of $629,652.98.

ProKidney Stock Performance

Shares of NASDAQ:PROK traded down $0.06 during midday trading on Monday, hitting $0.73. 577,297 shares of the company's stock traded hands, compared to its average volume of 683,193. The firm's fifty day moving average price is $1.00 and its two-hundred day moving average price is $1.50. ProKidney Corp. has a twelve month low of $0.46 and a twelve month high of $4.44. The company has a market cap of $214.52 million, a PE ratio of -1.33 and a beta of 1.52.

ProKidney (NASDAQ:PROK - Get Free Report) last posted its earnings results on Monday, March 17th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.14) by ($0.03). The firm had revenue of $0.08 million during the quarter. As a group, equities research analysts anticipate that ProKidney Corp. will post -0.57 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. Charles Schwab Investment Management Inc. grew its holdings in ProKidney by 150.6% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 749,718 shares of the company's stock valued at $1,439,000 after purchasing an additional 450,548 shares in the last quarter. The Manufacturers Life Insurance Company grew its stake in shares of ProKidney by 54.6% during the third quarter. The Manufacturers Life Insurance Company now owns 37,981 shares of the company's stock valued at $73,000 after acquiring an additional 13,415 shares in the last quarter. State Street Corp increased its position in shares of ProKidney by 16.2% during the third quarter. State Street Corp now owns 1,428,318 shares of the company's stock worth $2,742,000 after acquiring an additional 198,836 shares during the last quarter. XTX Topco Ltd purchased a new position in ProKidney in the third quarter valued at about $41,000. Finally, Barclays PLC grew its stake in ProKidney by 575.7% during the 3rd quarter. Barclays PLC now owns 146,321 shares of the company's stock valued at $281,000 after purchasing an additional 124,667 shares in the last quarter. 51.59% of the stock is owned by institutional investors and hedge funds.

ProKidney Company Profile

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease.